Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.68 |
| ▸ | HTR2A | P28223 | 15/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.68 |
| ▸ | DRD2 | P14416 | 12/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399709 | 0.89 | HTR1A (0.61) | HTR1AHTR2AKCNH2DRD2HTR7 | |
| SCHEMBL6397593 | 0.87 | HTR1A (0.56) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6399037 | 0.87 | HTR1A (0.68) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6400489 | 0.87 | HTR1A (0.63) | HTR1AHTR2AKCNH2DRD2HTR7 | |
| SCHEMBL6398868 | 0.86 | HTR1A (0.67) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6402195 | 0.86 | HTR1A (0.58) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6400727 | 0.85 | HTR1A (0.65) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6399771 | 0.84 | HTR1A (0.56) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6397588 | 0.83 | HTR1A (0.55) | HTR1AHTR2AKCNH2DRD2DRD3 | |
| SCHEMBL6399699 | 0.83 | HTR1A (0.61) | HTR1AHTR2AKCNH2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | claimed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | HTR1A 61/4885HTR2A 195/4885KCNH2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.